HK Stock Market Move | YIDU TECH (02158) rose more than 3% in intraday trading, assisting in the approval and listing of China's first intra-charge stem cell therapy drug.

YIDU TECH (02158) rose more than 3% during trading hours, with a rise of 3.22% as of the time of publication, reaching HK$4.49, with a turnover of HK$17.9299 million. On the news front, on January 2, 2025, the first stem cell therapeutic drug "Amy Metase Injectable" developed by YIDU TECH in Phase II and Phase III clinical trials was approved for market launch in China. The launch of this drug has promoted clinical exploration of stem cell therapy in multiple indications, marking an important milestone in the field of stem cell therapy in China. YIDU TECH, as a close partner of Platinum Excellent, played a key role in the project, providing SMO services in Phase II and Phase III clinical studies, with the entire project team supporting the national bureau's verification, laying a solid foundation for the successful approval of "Amy Metase Injectable". It is worth mentioning that while YIDU TECH has made significant breakthroughs in the field of biotechnology, its performance has also been very impressive. The financial report for the first half of the 2025 fiscal year shows that after adjusting for existing business management caliber EBITDA from the previous fiscal year turning losses into profits, YIDU TECH has continuously achieved profits exceeding RMB 27 million, and the mid-term profit level has basically remained consistent with the full year of the 2024 fiscal year, which is also the best level in the historical period.